○Kohei Mori¹, Takehiro Kawashiri¹, Mine Keisuke¹, Inoue Mizuki¹, Kudamatsu Hibiki¹, Kobayashi Daisuke¹, Shimazoe Takao¹ (1. Grad. Sci. Pharm. Sci., Kyushu Univ.)

○Takanobu Nadai¹, Katsuya Narumi², Ayako Furugen², Ken Iseki^2,3, Masaki Kobayashi² (1. Grad. Sch. Life. Sci., Hokkaido Univ. , 2. Fac. Pharm. Sci., Hokkaido Univ. , 3. Sch. Pharm. Sci., Health Sci. Univ. Hokkaido)

○Saori Deguchi¹, Suzu Yoshioka¹, Miku Nishida¹, Miri Komatsu¹, Hiroko Otake¹, Noriaki Nagai¹ (1. Pharm., Kindai Univ.)

○Hitomi Okamoto¹, Yoichi Tanaka², Yoshio Shibagaki^1,2, Katsuya Otori^1,2, Mitsuru Okuwaki^1,2 (1. Grad. Sch. Pharm., Kitasato Univ., 2. Sch. Pharm., Kitasato Univ.)

○Kouya Uchino¹, Hiroyuki Kawano², Tanaka Yasuyoshi ², Yuna Adaniya¹, Ai Asahara¹, Masanobu Deshimaru², Takuya Watanabe¹, Kubota Kaori¹, Shutaro Katsurabayashi^1,2, Shinichi Hirose^2,3, Katsunori Iwasaki¹ (1. Department of Neuropharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan, 2. Research Institute for the Molecular Pathogeneses of Epilepsy, Fukuoka University, Fukuoka, Japan, 3. General Medical Research Center, School of Medicine, Fukuoka University, Fukuoka, Japan)

○Kouichi Itoh¹, Taira Matsuo¹, Rie Komori¹, Yasuhiro Ishihara² (1. Kagawa Sch. of Pharmaceutical Sci., Tokushima Bunri Univ., 2. Grad. Sch. Integr. Sci. Life, Hiroshima Uni)